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Objectives:
 
 Current methods for estimating the cost of
illness inconsistently control for the effect of comorbid
conditions. This analysis examines the implications of
controlling for comorbid conditions on the estimated
cost of illness. These implications are illustrated using
the cost of osteoarthritis as an example.
 
Methods and Data:
 
 Medical claims data from 1996
were obtained for inpatient, outpatient, and pharmacy
services for members in four United HealthCare health
plans. Total annual costs for osteoarthritis (OA) were
compared to costs among an equal number of compari-
son members. Multivariate regression analysis was used
to compare the natural log of costs between the OA and
comparison groups under two alternative controls for
comorbid conditions: no controls, and controls for all
conditions.
 
Results:
 
 Controlling for no or all comorbid conditions
resulted in estimates of the annual cost of members
with OA that ranged between 261% and 151% of the
cost of members without OA, respectively.
 
Conclusions:
 
 Existing cost-of-illness estimates may seri-
ously underestimate the true cost by including statistical
controls for all comorbid conditions, or seriously over-
estimate the true cost by failing to control for enough
comorbid conditions. In the case of OA, the range of
potential bias is substantial.
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thritis.
 
Introduction
 
Managed care organizations, employers, govern-
ments, patients, and others responsible for manag-
ing health care costs rely on estimates of the cost
of specific illness to guide their cost-reducing strat-
egies. It is important, therefore, that estimates of
the cost of illness be accurate.
One key factor affecting the accuracy of a cost-
of-illness estimate is the selection of independent
variables to include in the statistical model used to
generate the estimate. In particular, the statistical
model must properly control for the presence of
comorbid conditions, because these conditions are
determinants of cost. If a comorbid condition is
caused by the disease of interest or by the treat-
ment of this disease, the costs of the comorbid con-
dition should be attributed to the disease. On the
other hand, the cost of comorbid conditions that
are not related to the disease of interest should not
be attributed to the disease. The problem, there-
fore, is to determine which comorbid conditions
should be included as statistical controls in a cost-
of-illness study.
This paper explores the implications of simplis-
tic estimates that control for no or all comorbid
conditions when estimating the incremental cost
of illness for a particular disease. To illustrate the
importance of choosing comorbid conditions cor-
rectly, the annual cost of osteoarthritis (OA) is es-
timated using two models: one that controls for all
comorbid conditions, and one that controls for no
comorbid conditions. The models are estimated
with data from a large, US managed care organi-
zation that provides coverage to both commercial
and Medicare members. Hence, the perspective of
the analysis is that of a US managed care system
(the managed care organization and its patients).
 
Methods
 
Econometric Modeling of Cost of Illness
 
In a typical cost-of-illness model, total costs in pa-
tients with a specific disease are compared to total
costs among patients without the disease, with the
difference being attributed to the disease. This com-
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parison is often made using linear regression that
also includes controls for age and sex, and may
also include controls for comorbid conditions:
where “Disease” is a binary variable equal to 1 if
the patient has the disease of interest, CC
 
1
 
 and
CC
 
2
 
 are binary variables representing two comor-
bid conditions, 
 

 
1
 
 are parameters to be estimated,
and 
 

 
 is a standard normal error term. The incre-
mental cost of the disease is given by the estimate
of the parameter 
 

 
1
 
. Additional binary variables
representing comorbid conditions (CC
 
i
 
) may be
included in the model.
The impact of including or excluding a comorbid
condition on the parameter estimate, and hence the
estimated cost, depends on whether the disease of
interest or its treatment causes the comorbid condi-
tion (i.e., the comorbid condition is the sequela of
the disease/treatment. Examples of “causally related”
comorbid conditions include hypertension and myo-
cardial infarction, diabetes and renal disease, and
depression and sexual dysfunction. Unrelated dis-
eases that are “co-occurring” include such pairings
as insomnia and osteoporosis or astigmatism and ir-
ritable bowel disease.
The estimated incremental cost of illness can be
biased by including or excluding causally related
or correlated comorbid conditions, or both (Table
1). Including a causally related comorbid condi-
tion as a control biases the estimated cost of ill-
ness, because all of the costs of the comorbid
condition are allocated to the comorbid condition
itself and none of the costs are allocated to the dis-
ease of interest. This approach is clearly wrong be-
Cost β0 β1Disease β2Ageβ3Gender β4CC1 β5CC2 ε
+ + +
+ + +
=
 
cause the disease of interest causes the comorbid
condition. By the same reasoning, excluding a caus-
ally related comorbid condition as a control does
not bias the results, because the costs of the comor-
bid condition are included in the parameter esti-
mate for the disease variable via the correlation be-
tween the two conditions.
If there is no causal relationship between the
disease of interest and the comorbid condition, the
estimate of the cost of illness will be biased only if
the two conditions are correlated and the comor-
bid condition is excluded from the analysis. Two
diseases can have no causal relationship but still
be correlated if the correlation is spurious; for ex-
ample, if the correlation occurs through a third
variable. For example, colon cancer and type II di-
abetes have no causal relationship, but they are
both correlated with age. The bias occurs because
the excluded variable is correlated with the vari-
able of interest. Excluding a relevant variable that
is correlated with regressors in the statistical model
biases the estimate [1].
 
Table 1
 
Sources of potential bias by comorbid conditions 
in cost-of-illness studies
 
Control for 
comorbid 
condition
Do not 
control for
comorbid 
condition
Causal relationship between
the two diseases Bias No bias
No causal relationship between
the two diseases
Correlation between the two 
diseases No bias Bias
No correlation between the two
diseases No bias No bias
 
Table 2
 
Comorbidities of osteoarthritis controlled for in estimating the cost of illness with model II
 
Comorbid condition ICD-9-CM diagnosis codes
Infectious and parasitic diseases 001.xx-139.xx
Cancer 140.xx-239.xx
Endocrine, nutritional and metabolic 240.xx-279.xx
Blood disorders 280.xx-289.xx
Mental disorders 290.xx-319.xx
Nervous system 320.xx-389.xx
Circulatory system 390.xx-459.xx
Respiratory system 460.xx-519.xx
Digestive system: lower 520.xx-530.xx, 534.xx, 535.1x-536.7x, 537.xx-569.81, 569.83-577.xx, 579.xx
Digestive system: upper 531.xx-533.xx, 535.0x, 536.8x, 536.9x, 569.82, 578.xx
Genitourinary system 580.xx-629.xx
Pregnancy complications 630.xx-677.xx
Skin disorders 680.xx-709.xx
Congenital anomalies 740.xx-759.xx
Perinatal conditions 760.xx-779.xx
Injury/poisoning 800.xx-999.xx
Other musculoskeletal conditions 720.xx-739.xx
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Example: Osteoarthritis
 
To illustrate the magnitude of potential bias intro-
duced by incorrectly specifying comorbid conditions
in cost-of-illness studies, we estimated two models
of the cost of osteoarthritis using data from a large,
US managed care organization. Model I does not
control for comorbid conditions, whereas Model
II controls for all comorbid conditions. Osteoar-
thritis is a good example for illustrating the im-
portance of proper specification of comorbid con-
ditions because it is correlated with many conditions
that appear, at least on the surface, to have no causal
relationship to arthritis. For example, a markedly
higher prevalence of cardiovascular disease, auditory
disease, respiratory disease and heme/lymphatic dis-
orders has been identified among people with OA
than among those without it [2].
Data for estimating these two models consist of
1996 inpatient, outpatient, and pharmacy claims
records from four United HealthCare managed
care plans located in the Northeast, Midwest, and
Southeast regions of the United States These claims
data represent the health care utilization experience
of approximately 868,000 commercial and 16,000
Medicare members. Each plan reimburses provid-
ers on a fee-for-service basis. All of the Medicare
lives were covered by a Medicare risk contract that
included a prescription drug benefit.
Patients with OA were defined as members
with: 1) two or more physician claims with a pri-
mary or secondary diagnosis of OA from a physi-
cian in a specialty likely to treat arthritis patients
(family practice, internal medicine, orthopedics, pe-
diatrics, rehabilitation medicine, podiatry, rheuma-
tology, or chiropractic); and 2) at least 31 consec-
utive days of enrollment in 1996. The 31-day
enrollment criterion maximizes the number of ob-
servations while excluding those enrollees who,
for all practical purposes, were not enrolled in the
plan. The ICD-9 codes (primary and secondary)
used to identify OA patients were 715.0x, 715.1x,
715.2x, 715.3x, 715.8x and 715.9x.
To reduce the amount of random variation in
the data, an equal number of nonarthritis patients
were selected using stratified random sampling of
the nonarthritis population, with the strata de-
fined as age group, sex, and health plan (the four
plans represented in the database). To be consis-
tent with the arthritis group, nonarthritis mem-
bers were also required to have: 1) at least one
 
Table 3
 
Summary statistics
 
OA Non-OA
Variable Mean Std. Mean Std.
PPPM cost $404.67 $741.68 $240.69 $1,887.94
Months enrolled 11.46 1.65 10.81 2.61
Age 0–44 13.3% 0.339 13.3% 0.340
Age 45–54 27.7% 0.447 27.7% 0.447
Age 55–64 31.1% 0.463 31.1% 0.463
Age 65+ 27.9% 0.449 27.9% 0.449
Female 59.1% 0.492 59.1% 0.492
Spouse 29.7% 0.457 26.8% 0.443
Dependent 0.4% 0.065 6.4% 0.244
Midwest plan 1 27.8% 0.448 27.8% 0.448
Midwest plan 2 31.7% 0.465 31.7% 0.465
Northeast plan 14.1% 0.348 14.1% 0.348
Infectious and parasitic diseases 7.5% 0.264 4.9% 0.215
Cancer 8.4% 0.277 7.4% 0.262
Endocrine, nutritional and metabolic 30.1% 0.459 18.2% 0.386
Blood disorders 4.1% 0.199 2.0% 0.139
Mental disorders 11.3% 0.316 6.3% 0.243
Nervous system 25.9% 0.438 18.2% 0.386
Circulatory system 44.5% 0.497 29.1% 0.454
Respiratory system 28.7% 0.452 20.3% 0.402
Digestive system: lower 14.5% 0.352 8.4% 0.278
Digestive system: upper 4.2% 0.200 1.7% 0.131
Genitourinary system 18.8% 0.391 13.7% 0.344
Pregnancy complications 0.1% 0.029 0.2% 0.039
Skin disorders 13.2% 0.338 9.0% 0.286
Congenital anomalies 2.5% 0.156 0.8% 0.092
Perinatal conditions 0.0% 0.018 0.1% 0.026
Injury/poisoning 24.0% 0.427 9.7% 0.295
Other musculoskeletal conditions 48.8% 0.500 13.0% 0.336
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physician claim; 2) no physician claims for arthri-
tis; and 3) at least 31 consecutive days of enroll-
ment in 1996.
Costs in this study were defined as the actual
per-patient, per-month (PPPM) amounts paid to
providers plus any member cost-sharing amounts
(copayments and deductibles) in the 1996 medi-
cal and pharmacy claims. The costs represent the
amounts received by providers in a managed care
system (paid by the managed care organization
and by the patients). Definitions of comorbid con-
ditions used in Model II are presented in Table 2.
Models I and II include controls for age (45–54
years, 55–64 years and 65 years and above), gen-
der, health care plan, and dependent status (spouse,
dependent, or employee). All patients in the 65 +
category were covered by a Medicare risk plan. An-
alyzing the data on a PPPM basis controlled dura-
tion of enrollment. To normalize the highly skewed
cost data, the natural logarithm of total costs is
used as the dependent variable. As a result, the
percentage difference in costs attributable to ar-
thritis is calculated as (100*(e
 

 

 
1)). Finally, test-
ing of both models for heteroskedasticity using
standard methods indicated that error variances
were not constant (
 
p
 
 
 
 
 
.001) [3]. Consequently,
all statistical tests were based on a corrected cova-
riance matrix [3]. All estimates were generated with
SAS statistical software (SAS Institute, Cary, NC,
1994) [4].
 
Results
 
Based on the patient selection criteria, 5920 mem-
bers were classified as having OA, 862 of whom
were covered by Medicare. Because an equal num-
ber of patients in the nonarthritis comparison
group were also selected, the number of members
used in the analysis was 11,840. Summary statis-
tics and demographic information for patients in-
cluded in the analysis are presented in Table 3.
The results from estimating Models I and II are
presented in Table 4. In Model I, which does not
control for comorbid conditions, the estimated co-
efficient on the OA variable is 0.959 (
 
p
 
 
 
 
 
.001)
which, after transformation, implies that OA pa-
tients cost, on average, 2.61 times as much as
patients without OA in 1996. In contrast, the pa-
rameter estimate from Model II, which does in-
clude controls for comorbid conditions, is only
 
Table 4
 
Effect of controlling for no or all comorbid conditions in cost-of-illness estimates for osteoarthritis
 
Model I: Control for no comorbid conditions Model II: Control for all comorbid conditions
Estimate % Difference with comparison group Estimate % Difference with comparison group
Intercept 4.031 n/a 3.636 n/a
Osteoarthritis 0.959 160.846 0.410 50.619
Age 45–54 0.173 18.919 0.062* 6.410
Age 55–64 0.438 54.939 0.192 21.192
Age 65+ 0.394 48.360
 

 
0.018*
 

 
1.776
Female 0.097 10.157 0.001* 0.130
Spouse
 

 
0.061
 

 
5.954
 

 
0.037*
 

 
3.603
Dependent
 

 
0.563
 

 
43.037
 

 
0.416
 

 
34.039
Midwest plan 1
 

 
0.034
 

 
3.296
 

 
0.062*
 

 
5.981
Midwest plan 2
 

 
0.156*
 

 
14.484
 

 
0.297
 

 
25.684
Northeast plan
 

 
0.003*
 

 
0.292 0.047* 4.859
Infectious and parasitic diseases 0.177 19.412
Cancer 0.701 101.669
Endocrine, nutritional and metabolic 0.340 40.469
Blood disorders 0.498 64.592
Mental disorders 0.361 43.534
Nervous system 0.327 38.744
Circulatory system 0.601 82.484
Respiratory system 0.373 45.214
Digestive system: lower 0.503 65.326
Digestive system: upper 0.313 36.811
Genitourinary system 0.390 47.686
Pregnancy complications 1.411 310.149
Skin disorders 0.128 13.627
Congenital anomalies 0.368 44.549
Perinatal conditions 1.041 183.103
Injury/poisoning 0.531 70.072
Other musculoskeletal conditions 0.514 67.125
N 11,840 11,840
Adjusted R
 
2
 
0.14 0.40
 
*Not statistically significant (
 
P
 
 
 

 
. 05).
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0.410 (
 
p
 
 
 
 
 
.001). Again, after transformation this
estimate indicates that in 1996, OA patients cost
only 1.51 times as much as patients who did not
have OA. Thus, including controls for comorbid
conditions markedly changes the estimated cost of
treating OA.
 
Discussion
 
Cost-of-illness studies across various diseases com-
monly exclude controls for comorbid conditions.
For example, recent cost studies in the areas of bipo-
lar disorder [5] depression [6], diabetes [7–9] and
asthma [10] all estimate the cost of these diseases us-
ing retrospective data without controlling for comor-
bid conditions. The results of our work suggest that
these analyses probably overstated the incremental
costs of these diseases. In fact, Simon et al. found
that adding a control for chronic disease reduced the
estimated incremental cost of depression [11].
In the area of arthritis, two studies estimated
the cost without controlling for comorbid condi-
tions. Gabriel et al. [2] estimated that the annual
cost of treating OA patients was approximately
1.92 ($2654/$1388) times the annual cost of treat-
ing non-OA patients using 1987 data from Olmsted
County, Minnesota. MacLean et al. [12] estimated
that OA patients cost approximately 2.15 times more
annually than non-OA patients in 1993 dollars us-
ing managed care claims data. By comparison, we
estimated that OA patients cost approximately
2.61 times as much as non-OA patients using Model
I, which also did not include controls for comor-
bid conditions.
In contrast, Fishman et al. [13] estimated the
cost of arthritis in a model that controlled for all
comorbid conditions, including gastrointestinal dis-
ease, which is related to the cost of OA [14]. As
we predicted, they found a smaller annual cost for
arthritis. Specifically, they estimated that arthritis
patients cost about 1.50 times more annually than
nonarthritis patients using 1992 managed care
data. This estimate is essentially the same as that
produced by Model II above, which also con-
trolled for all comorbid conditions.
A key limitation to the method of analysis we
have proposed here is that it requires the ability to
identify a priori those conditions that are related to
the disease of interest so that they can be excluded
as controls in the model. In some cases, medical and
epidemiology data do not clearly define the causal
relationship between diseases. In such cases, incor-
rectly assuming that a comorbid condition is related
to the disease (and excluding it from the model) will
result in an estimated cost of illness that is too large
if the two diseases are actually correlated. On the
other hand, erroneously classifying conditions as
unrelated to the disease of interest (and including it
in the model) results in an estimated cost of illness
that is too small if the two conditions are correlated.
The estimated cost of OA presented here incor-
porates this limitation and others. For example, the
results may be biased and/or inefficient because
critical determinants of cost such as race, health
habits, family history, education level, and so on
were not available for inclusion in the analysis.
Further, the estimates may contain classification
errors. OA is a chronic disease, so it is likely to be
identified on claims only when it is first diagnosed.
Consequently, it is likely that there are a number
of OA patients that were incorrectly classified as
not having OA in our analysis.
In conclusion, we believe that accurate esti-
mates of cost of illness cannot simply control for
all or no comorbid conditions. Rather, when pos-
sible, they must control for those comorbid condi-
tions that are causally unrelated to, but correlated
with, the disease of interest.
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